WATCH: Benjamin Weinberg, MD, discusses how the @fda.gov approval of daraxonrasib for metastatic pancreatic adenocarcinoma might fuel future research in this disease. #pancsm #oncology
Read more about the approval: www.onclive.com/view/fda-app...
WATCH: Benjamin Weinberg, MD, discusses how the @fda.gov approval of daraxonrasib for metastatic pancreatic adenocarcinoma might fuel future research in this disease. #pancsm #oncology Read more about the approval: www.onclive.com/view/fda-app...
0 vue
Publié le 16/10/2026 21:04
1:43
WATCH: Benjamin Weinberg, MD, discusses how the @fda.gov approval of daraxonrasib for metastatic pancreatic adenocarcinoma might fuel future research in this disease. #pancsm #oncology
Read more about the approval: www.onclive.com/view/fda-app...
1 commentaire
?
Daraxonrasib hits the active, GTP-bound RAS(ON) state across variants, so it reaches the G12D and G12V tumors that make up most of pancreatic cancer, where G12C (OFF-state) inhibitors don't apply. Keeping the RAS inhibitor classes straight is exactly what our mind maps are for.